Skip Navigation



Annals of Oncology Advance Access published online on May 25, 2006
Annals of Oncology, doi:10.1093/annonc/mdl102
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/8/1320    most recent
mdl102v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gietema, J. A.
Right arrow Articles by Eskens, F. A. L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gietema, J. A.
Right arrow Articles by Eskens, F. A. L. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received October 19, 2005
Revised March 23, 2006
Accepted March 30, 2006

original article

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors

J. A. Gietema 1 *, R. Hoekstra 2, F. Y. F. L. de Vos 1, D. R. A. Uges 3, A. van der Gaast 2, H. J. M. Groen 4, W. J. Loos 2, R. A. Knight 5, R. A. Carr 5, R. A. Humerickhouse 5, and F. A. L. M. Eskens 2

1 Department of Medical Oncology, University of Groningen and University Medical Center Groningen, Groningen
2 Department of Medical Oncology, Erasmus MC, Rotterdam, the Netherlands
3 Department of Pharmacy, University of Groningen and University Medical Center Groningen, Groningen
4 Department of Pulmonology, University of Groningen and University Medical Center Groningen, Groningen
5 Abbott Laboratories, Chicago, IL, USA

* To whom correspondence should be addressed.
J. A. Gietema, E-mail: j.a.gietema{at}int.umcg.nl


  Abstract

Background: The aim of the study was to determine the safety profile, pharmacokinetics and potential drug interactions of the angiogenesis inhibitor ABT-510 combined with gemcitabine-cisplatin chemotherapy in patients with solid tumors.

Patients and methods: Patients with advanced solid tumors received gemcitabine 1250 mg/m2 intravenously (i.v.) on days 1 and 8 and cisplatin 80 mg/m2 on day 1 of a 3-week cycle in combination with ABT-510. ABT-510 was administered subcutaneously twice daily at doses of 50 mg or 100 mg. Plasma samples for pharmacokinetics were obtained on days 1 (gemcitabine, cisplatin as single agents), 15 (ABT-510 as single agent) and 22 (gemcitabine, cisplatin and ABT-510 as combination).

Results: Thirteen patients received ABT-510 as either 50 mg b.i.d. (seven patients) or 100 mg b.i.d. (six patients) in combination with gemcitabine-cisplatin. The most common reported adverse events reflected the known toxicity profile induced by gemcitabine-cisplatin without ABT-510. One episode of hemoptysis occurred in a patient with non-small-cell lung cancer (NSCLC) after 13 days of treatment. No clinically significant pharmacokinetic interactions between ABT-510, gemcitabine and platinum were observed. Three partial responses were observed in 12 evaluable patients (one head and neck cancer, one melanoma and one NSCLC).

Conclusions: Combining ABT-510 at doses of 50 mg and 100 mg with gemcitabine-cisplatin is feasible. Pharmacokinetic interactions were not observed and adding ABT-510 does not appear to increase toxicity.

Keywords: ABT-510; angiogenesis inhibitor; cisplatin; gemcitabine; phase I.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
C. H. Mom, J. Verweij, C. N.A.M. Oldenhuis, J. A. Gietema, N. L. Fox, R. Miceli, F. A.L.M. Eskens, W. J. Loos, E. G.E. de Vries, and S. Sleijfer
Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
Clin. Cancer Res., September 1, 2009; 15(17): 5584 - 5590.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
J. CORONELLA, L. LI, K. JOHNSON, S. PIRIE-SHEPHERD, G. ROXAS, and N. LEVIN
Selective Activity Against Proliferating Tumor Endothelial Cells by CVX-22, A Thrombospondin-1 Mimetic CovX-BodyTM
Anticancer Res, June 1, 2009; 29(6): 2243 - 2252.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
R. Hasina, L. E. Martin, K. Kasza, C. L. Jones, A. Jalil, and M. W. Lingen
ABT-510 Is an Effective Chemopreventive Agent in the Mouse 4-Nitroquinoline 1-Oxide Model of Oral Carcinogenesis
Cancer Prevention Research, April 1, 2009; 2(4): 385 - 393.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. D. Roberts, J. S. Isenberg, L. A. Ridnour, and D. A. Wink
Nitric Oxide and Its Gatekeeper Thrombospondin-1 in Tumor Angiogenesis
Clin. Cancer Res., February 1, 2007; 13(3): 795 - 798.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.